Recruiting
Observational
Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19
Condition(s) studied
COVID-19Post-COVID-19 Syndrome
Investigational drug(s) / intervention(s)
Dynamic Vessel Analyzer (DVA)Fourier domain optical coherence tomography (FDOCT)Optical coherence tomography (OCT)Laser Speckle Flowgraphy (LSFG)Proteomics and Metabolites in Plasma, tear fluid and finger sweat
Dynamic Vessel Analyzer (DVA): Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
Fourier domain optical coherence tomography (FDOCT): Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
Optical coherence tomography (OCT): Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
Laser Speckle Flowgraphy (LSFG): Normalized blur and Relative flow volume will be assessed using the LSFG
Proteomics and Metabolites in Plasma, tear fluid and finger sweat: Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
Study summary
The Study objective is to measure retinal neurovascular coupling and blood flow parameters in patients previously infected with COVID-19, long COVID-19 and healthy age- and sex- matched control subjects
Eligibility
Inclusion Criteria:
Inclusion criteria for healthy subjects
* Men and women aged over 18 years
* Non-smokers
* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
* No previous history of COVID-19 infection
* Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests
* Negative PCR test for SARS-CoV-2
* Normal ophthalmic findings, ametropy \< 6 Dpt.
Inclusion criteria for subjects with history of COVID-19 infection
* Men and women aged over 18 years
* Non-smokers
* History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) within the last 6 months
* Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibody tests
* Negative PCR test for SARS-CoV-2
Inclusion criteria for subjects with long COVID-19
* Men and women aged over 18 years
* Non-smokers
* History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history)
* Positive testing for SARS-CoV-2 seroprevalence
* Negative PCR test for SARS-CoV-2
* Long Covid according to the latest WHO-Guidelines
Exclusion Criteria:
Any of the following will exclude a healthy control subject from the study:
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Presence or history of a severe medical condition as judged by the clinical investigator
* Participation in a clinical trial in the 3 weeks preceding the study
* Blood donation during the previous three weeks
* History or family history of epilepsy
* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
* Best corrected visual acuity \< 0.8 Snellen
* Pregnancy, planned pregnancy or lactatin
* History of epilepsia
Any of the following will exclude a subject with history of COVID-19 infection from the study:
* Blood donation during the previous three weeks
* History or family history of epilepsy
* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
* Best corrected visual acuity \< 0.8 Snellen
* Ametropy \>6 Dpt
* Pregnancy, planned pregnancy or lactating
* History of epilepsia
Any of the following will exclude a subject with long COVID-19 from the study:
* Blood donation during the previous three weeks
* History or family history of epilepsy
* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
* Best corrected visual acuity \< 0.8 Snellen
* Ametropy \>6 Dpt
* Pregnancy, planned pregnancy or lactating
* History of epilepsia
* Diabetes mellitus
Primary outcome measure(s)
- Retinal neurovascular coupling — Day 0
Retinal neurovascular coupling will be assessed using the DVA
Trial sites (1)
| Facility | City | Region | Status |
| Medical University of Vienna, Department of Clinical Pharmacology |
Vienna |
State of Vienna |
Recruiting |
More Medical University of Vienna trials in Austria
Other trials for the same condition